In a Phase 1 Trial, UB-312 Lowers α-Synuclein in Parkinson's Disease.

Published Date: 21 Mar 2024

Research presented at AD/PD 2024 revealed that UB-312 antibodies lower α-synuclein levels in Parkinson disease patients' cerebrospinal fluid, according to new results from a phase 1 trial.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Remote monitoring can improve recovery from cancer surgery

2.

Intractable cancers may respond better to treatment when using new radiation and high-performance computing.

3.

A Win for AI in Cancer; 2025's Transformative Drugs; FDA Clarifies 'Underway' Trials

4.

Conditional EU Nod for Weekly Pill in Pediatric Glioma

5.

high response rate when using a bispecific antibody to treat R/R multiple myeloma.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot